Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) is a Healthcare company (Biotechnology) with a market capitalization of $549M. The Maz Rating grades it against the other companies in its sector.
Orchestra BioMed Holdings, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.97, Orchestra BioMed Holdings, Inc. trades at 17.7x sales and 24184.1x book value. Over the last twelve months it generated about $31M of revenue and a net loss of $70M. It runs a gross margin of 99.4%, an operating margin of -195.4% and a net margin of -182.5%. It shows return on equity of -140.2%, return on invested capital of -64.6% and a free cash flow yield of -11.7%. On the balance sheet: a debt-to-equity ratio of 3.92 and a current ratio of 7.25. Over the past 52 weeks the share price ranged from $3.46 to $7.45, with a beta of 0.55.
Orchestra BioMed Holdings, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.